10-K · March 3, 2026
Enliven is a clinical-stage small-molecule biopharma focused on ELVN-001 (BCR-ABL TKI). The 10-K highlights encouraging Phase 1/1b efficacy and tolerability data (MMR and DMR rates) and a plan to initiate a 2L+ Phase 3…
Earnings analysis · 10-Q
ELVN earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Enliven Therapeutics reported a net loss of $23.6 million for Q1 2026, an improvement from a loss of $28.5 million in the prior year, translating to a diluted EPS of -$0.38 compared to -$0.57 a year prior. Despite a…
Read full summary
Enliven Therapeutics reported a net loss of $23.6 million for Q1 2026, an improvement from a loss of $28.5 million in the prior year, translating to a diluted EPS of -$0.38 compared to -$0.57 a year prior. Despite a continuation of negative cash flows from operations, the company reduced R&D expenses significantly to $20.7 million from $24.9 million year-over-year.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.38
What stood out
-
Improvement in EPS
Diluted EPS improved to -$0.38 from -$0.57 year-over-year.
-
Reduced R&D Expenses
R&D expenses decreased to $20.7 million compared to $24.9 million in Q1 2025.
-
Increased Cash Position
Cash, cash equivalents and marketable securities reached $452.4 million as of March 31, 2026.
-
Rise in Other Income
Other income increased to $4.2 million from $3.1 million the previous year.
-
Decrease in Total Operating Expenses
Total operating expenses fell to $27.8 million compared to $31.7 million in Q1 2025.
-
Strong Liquidity Position
Existing cash and marketable securities sufficient to fund operations into 2029.
What to watch
-
Continuing Negative Cash Flow
Q1 2026 reported cash used in operations of $19.3 million, down from $24.1 million in Q1 2025.
-
High Dependency on ELVN-001
Company significantly relies on successful development and commercialization of ELVN-001.
-
Potential for Future Funding Needs
Substantial additional capital required for ongoing developments and operations, raising risk of dilution.
Management's outlook
No numeric revenue or EPS guidance provided; improvements are anticipated with ongoing developments.
Earlier filings 4
10-Q · November 12, 2025
Enliven reported Q3 2025 net loss of $20,148,000 (EPS $(0.32)), an improvement from Q3 2024 net loss of $23,156,000 (EPS $(0.48)). The quarter saw lower total operating expenses of $25,096,000 (down from $27,068,000)…
10-K · March 13, 2025
Enliven is a chemistry-led, clinical-stage oncology company advancing two lead small-molecule programs (ELVN-001 for BCR‑ABL/CML and ELVN-002 for HER2-driven cancers) with encouraging early-stage clinical signals. The…
10-Q · November 13, 2024
Enliven reported a Q3 net loss of $23,156,000 (EPS $(0.48)), compared with a net loss of $20,769,000 (EPS $(0.51)) in Q3 2023; operating expenses rose to $27,068,000 from $24,248,000. The company ended the quarter with…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.